Flagship-backed Generate raises $273M as its first drugs move to the clinic
Bio Pharma Dive
SEPTEMBER 14, 2023
Since 2019, Generate has raised nearly $700 million in private financing and has now brought a monoclonal antibody into Phase 1 testing.
Thu.Sep 14, 2023
300 
Astellas to build drug production facility in Ireland
Pharmaceutical Technology
SEPTEMBER 14, 2023
Astellas Pharma is submitting a planning application for the construction of a new drug production facility in Ireland.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
UK biotech AlveoGene launches with plans for inhaled gene therapy
Bio Pharma Dive
SEPTEMBER 14, 2023
The company is working on a treatment of alpha-1 antitrypsin deficiency, which it claims it can deliver direct to lung cells via a nebulizer.
Improving health equity in Europe’s small countries: How can we remove the barriers to access?
Pharmaceutical Technology
SEPTEMBER 14, 2023
Ensuring equitable access to medicines is a key challenge for many governments, particularly those of smaller nations. Pharmaceutical Technology reviews the data and explores European initiatives to improve the situation.
RayzeBio, Neumora price some of biotech’s largest IPOs this year
Bio Pharma Dive
SEPTEMBER 14, 2023
Pricing of the companies’ IPOs comes after a big day for Wall Street, which saw the SoftBank-owned chip maker Arm pull off the year’s largest new stock offering.
FDA accepts Madrigal’s liver disease therapy NDA for review
Pharmaceutical Technology
SEPTEMBER 14, 2023
The US FDA has accepted Madrigal Pharmaceuticals’ new drug application (NDA) for liver disease therapy resmetirom for review.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
AbCellera and Incyte partner for development of cancer antibodies
Pharmaceutical Technology
SEPTEMBER 14, 2023
AbCellera and Incyte have entered a partnership for the discovery and development of therapeutic antibodies in oncology.
RayzeBio’s $311M, Neumora’s $250M IPOs Among Biotech’s Largest This Year
BioSpace
SEPTEMBER 14, 2023
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
ICON partners with US Government for clinical trials of Covid-19 vaccines
Pharmaceutical Technology
SEPTEMBER 14, 2023
ICON will conduct Phase IIb clinical trials for the US BARDA-selected Covid-19 vaccine candidates as part of ‘Project NextGen’.
A World Alzheimer's Month resource roundup
Antidote
SEPTEMBER 14, 2023
Alzheimer’s disease, the most prevalent type of dementia , is diagnosed in more than 6 million Americans. Estimates project that by 2050, 13 million individuals will be diagnosed with Alzheimer’s disease. This condition ranks among the top 10 causes of death in the United States, profoundly impacting those diagnosed, their loved ones, and their caregivers.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmazz and Sun Pharma sign licence deal for Tyvalzi launch in India
Pharmaceutical Technology
SEPTEMBER 14, 2023
Pharmazz and Sun Pharma have signed a licence agreement for the marketing of Tyvalzi (Sovateltide) in India.
Busting common myths about lab automation
Drug Discovery World
SEPTEMBER 14, 2023
Ernesto Staroswiecki, Senior Manager, R&D, at Beckman Coulter Life Sciences takes readers through common lab automation myths. Many clinical and research laboratories today are having to do more with less: faced with ongoing staffing shortages, increased workloads, and budgetary constraints, many laboratory managers are feeling the stress, which is where the benefits of automation can be truly realised for labs in both academia and industry.
NME 2 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
NME 2 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor.
UKRI report reveals impact of COVID-19 research and innovation funding
Pharma Times
SEPTEMBER 14, 2023
The report highlights steps needed to ensure future pandemics are handled effectively - News - PharmaTimes
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
ZE-460134 by Eilean Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
ZE-460134 is under clinical development by Eilean Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Rome Therapeutics adds $72 million to Series B round to harness “dark genome”
Outsourcing Pharma
SEPTEMBER 14, 2023
The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.
(Islatravir + ulonivirine) by Merck for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
(Islatravir + ulonivirine) is under clinical development by Merck and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).
Digital Medicine in Pharma: A Marketers’ Guide for Launch, Promotion and Life Cycle Management
Intouch Solutions
SEPTEMBER 14, 2023
Digital medicine is emerging as a revolutionary field that can transform the entire spectrum of healthcare, from proactive prevention to effective treatment of diverse medical conditions. Unlike traditional pharmaceutical medications, digital medicine products need to speak to the clinical, economic and technological benefits to differentiate themselves from competitors.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
CD123-targeted CAR-NK by Chongqing Precision Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Refractory Acute Myeloid Leukemia.
Exelixis licenses AI-designed cancer drug from Insilico Medicine
Outsourcing Pharma
SEPTEMBER 14, 2023
Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.
BCMA-GPRC5D CAR-T Cells by Guangzhou Bio-gene Technology for Refractory Multiple Myeloma: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Refractory Multiple Myeloma.
Anavex’s Blarcamesine Slows Cognitive Decline in Alzheimer’s Patients
BioSpace
SEPTEMBER 14, 2023
Following a controversial Rett Syndrome trial last year, Anavex Life Sciences’ blarcamesine has claimed another clinical victory—this time in an Alzheimer’s disease Phase IIb/III study.
Roles and Responsibilities of Specialized Clinical Supply Experts
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
CD123-targeted CAR-NK by Chongqing Precision Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Relapsed Acute Myeloid Leukemia.
UK government invests £200m to boost NHS resilience this winter
Pharma Times
SEPTEMBER 14, 2023
The funding will reduce waiting lists and ease the demand on the NHS during Winter - News - PharmaTimes
BCMA-GPRC5D CAR-T Cells by Guangzhou Bio-gene Technology for Relapsed Multiple Myeloma: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Relapsed Multiple Myeloma.
Congenica and myTomorrows team up to improve patient access to precision oncology
Outsourcing Pharma
SEPTEMBER 14, 2023
A partnership deal between the Dutch digital health company Congenica and clinical trial platform provider myTomorrows will see the companies pooling their technologies to help more patients receive precision oncology treatments.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
LY-3885125 by Eli Lilly and Co for Non Alcoholic Fatty Liver Disease (NAFLD): Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
LY-3885125 is under clinical development by Eli Lilly and Co and currently in Phase I for Non Alcoholic Fatty Liver Disease (NAFLD).
FDA, manufacturers make progress in resolving key cancer drug shortages: White House
Fierce Pharma
SEPTEMBER 14, 2023
While there's certainly more work to do, the U.S. | Efforts from regulators and manufacturers have brought the U.S. supply of cisplatin back to nearly 100% of pre-shortage levels, according to the White House. The moves are “greatly alleviating the shortages of carboplatin,” too, the White House said.
AstraZeneca’s Alexion Reaches $125M Settlement in Soliris Sales Lawsuit
BioSpace
SEPTEMBER 14, 2023
After nearly seven years, the company’s rare diseases arm Alexion has reached a settlement in an investors’ lawsuit over alleged unethical sales practices for its hemoglobinuria therapy Soliris.
LY-3885125 by Eli Lilly and Co for Dyslipidemia: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 14, 2023
LY-3885125 is under clinical development by Eli Lilly and Co and currently in Phase I for Dyslipidemia.
Accelerating Clinical Supply Through Integrated Drug Development
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Let's personalize your content